Interleukin Two Results!

The Rheum Ribbon Panel votes for the Interleukin Two (final round) are here!  Avacopan has been crowned the winning rheumatology concept, and congratulations to Rheum Boss for having a perfect bracket in the first ever RheumMadness tournament.  But the real winners are all the participants who engaged in a collaborative learning experience with the rheumatology community.  This was so much fun!

What’s Next?

All participants will receive a Qualtrics survey invitation so we can learn from this year’s tournament and make it even better next year.  We are interested in hearing everyone’s responses, from those who tweeted every day about RheumMadness to those who submitted a bracket last minute and are not on social media.  Tell us what you think!

The Results

Keep scrolling to find out how your bracket is doing, then tell us your reaction on Twitter and/or the Facebook group using #RheumMadness. You can also find even more detailed bracket results directly on the Challonge website here: https://challonge.com/RheumMadness2021/predictions

Click here for a downloadable PDF of the Interleukin Two results

How did your bracket do?

Each bracket title is a link that takes you to the Challonge.com site where you will be able to see all of the predictions entered for that bracket.

  Rank Score Picks
Rheum BOSS

Avacopan, FAST Study, VEXAS, SEMIRA

1 32 15 / 15
No Rheum For Error

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

2 30 14 / 15
May the best man win!

Avacopan, FAST Study, VEXAS, SEMIRA

3 30 13 / 15
Sinead Maguire

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

4 29 13 / 15
Advocate FTW

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

4 29 13 / 15
Avacopan ftw

Avacopan, FAST Study, VEXAS, SEMIRA

6 29 12 / 15
Cut the nets/steoids

Avacopan, SEMIRA, VEXAS, FAST Study

7 28 14 / 15
RheumMadnessIsAwesome

Avacopan, SEMIRA, VEXAS, FAST Study

7 28 14 / 15
RheumWins

Avacopan, SEMIRA, VEXAS, FAST Study

7 28 14 / 15
Rheumothorax

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

10 28 12 / 15
Rookie C5a inhibitor edges out SAMIRA with its promise of vasculitis remission AND less steroids. A finals match-up showing that we are FINALly moving beyond high dose steroids.

Avacopan, SEMIRA, VEXAS, FAST Study

11 27 13 / 15
KWB

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

12 27 11 / 15
 Prednisone is Poison — mightymab

Avacopan, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

13 26 11 / 15
DFM

Avacopan, PRIME Cells, VEXAS, SEMIRA

14 25 12 / 15
CCHMC Peds Rheum Fellows

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

14 25 12 / 15
Game of Madness: To Conquer to Rule

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

14 25 12 / 15
Dr. Willie

Avacopan, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

14 25 12 / 15
What’s a bracket?

Avacopan, ACR Gout Guidelines, VEXAS, SEMIRA

14 25 12 / 15
Untitled

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

19 25 9 / 15
 AvaPoCan! — Thanks4theComplement

Avacopan, SEMIRA, VEXAS, ACR Gout Guidelines

20 24 11 / 15
 My Winning Prediction — StephenSlade

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

21 23 11 / 15
Just Dua It

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

21 23 11 / 15
Avocopan Avengers

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

21 23 11 / 15
Avacopan Beats Knee PT at the Buzzer

Avacopan, PT vs. GC Injection for Knee OA, IgG4-RD Classification Criteria, FAST Study

21 23 11 / 15
Ruairí Floyd Prediction

Avacopan, Harms of Short Term Steroids, VEXAS, PRIME Cells

25 22 10 / 15
Didem

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

25 22 10 / 15
All About Avacopan

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

25 22 10 / 15
Perry Fuchs’ Bracket

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

25 22 10 / 15
 CYCBI — ChangUCanSpare

Avacopan, SEMIRA, Anti-CD38 in Refractory SLE, Synovial B Cells & Therapy Response

25 22 10 / 15
Rheum’sYourDaddy

Avacopan, Synovial B Cells & Therapy Response, VEXAS, PT vs. GC Injection for Knee OA

25 22 10 / 15
Irelande Douze Pointes

Avacopan, Harms of Short Term Steroids, VEXAS, FAST Study

31 22 9 / 15
 psufka — paulsufka

Avacopan, UK Frost for Frozen Shoulder, IgG4-RD Classification Criteria, FAST Study

32 21 9 / 15
Avacopanhandle

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

32 21 9 / 15
Rheumania

Avacopan, Harms of Short Term Steroids, VEXAS, Synovial B Cells & Therapy Response

32 21 9 / 15
“Bye Bye Bye” Steroids

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, Harms of Short Term Steroids

35 20 9 / 15
XxFlare_BearxX

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

35 20 9 / 15
Nostradamus

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

37 20 8 / 15
Penelope Proactive Patient’s Prediction

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

37 20 8 / 15
Rheumba

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

37 20 8 / 15
Rheum’sYourDaddy

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

37 20 8 / 15
Rheum for Rheum Madness

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

41 19 8 / 15
 GoComplements — saikrishna133

Avacopan, Harms of Short Term Steroids, IgG4-RD Classification Criteria, Synovial B Cells & Therapy Response

41 19 8 / 15
Avacopan for ANCA vasculitis… now have to spell it right! (not “avacpoan” like on the list here https://sites.duke.edu/rheummadness/bracket-and-scouting-reports/ :))

Avacopan, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

43 19 7 / 15
Resident gone (Rheum)Mad

SEMIRA, Avacopan, VEXAS, FAST Study

44 18 11 / 15
 Fabulous FebuX — magnifique2020

FAST Study, Avacopan, IgG4-RD Classification Criteria, UK Frost for Frozen Shoulder

45 18 10 / 15
Rheumie

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

46 18 7 / 15
Vasculitis winner

PEXIVAS, FAST Study, VEXAS, SEMIRA

47 17 11 / 15
Blys FTW

Belimumab for Lupus Nephritis, FAST Study, VEXAS, SEMIRA

48 16 10 / 15
Untitled

PEXIVAS, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

49 15 10 / 15
Vexas for win

VEXAS, FAST Study, Belimumab for Lupus Nephritis, SEMIRA

50 15 9 / 15
Rheum_L

VEXAS, PRIME Cells, Avacopan, SEMIRA

51 14 11 / 15
 LeadershipTest — DavidLeverenz

FAST Study, RP Subtypes, Avacopan, PT vs. GC Injection for Knee OA

52 14 9 / 15
Criscione for the “W”

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, SEMIRA

52 14 9 / 15
Get VEXED by VEXAS!

VEXAS, FAST Study, PEXIVAS, PT vs. GC Injection for Knee OA

52 14 9 / 15
Belim u me

Belimumab for Lupus Nephritis, FAST Study, VEXAS, Harms of Short Term Steroids

52 14 9 / 15
 ESR — esr_

VEXAS, SEMIRA, Avacopan, ACR Gout Guidelines

56 13 10 / 15
Guy Katz

VEXAS, PRIME Cells, Avacopan, SEMIRA

56 13 10 / 15
gOUTisIN

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

58 13 8 / 15
idkijustlikegout

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

58 13 8 / 15
Void the ‘Roid

SEMIRA, Avacopan, RP Subtypes, FAST Study

60 13 7 / 15
Tincan

VEXAS, PT vs. GC Injection for Knee OA, Avacopan, FAST Study

61 12 9 / 15
Roid Rules

Synovial B Cells & Therapy Response, VEXAS, Avacopan, SEMIRA

61 12 9 / 15
No Rheum for Steroids!

PEXIVAS, FAST Study, Anti-CD38 in Refractory SLE, SEMIRA

63 12 7 / 15
NETosis: what is dead may never die

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, PRIME Cells

64 11 9 / 15
PLEXING CAN BE TAXING AND NEEDLESS ESPECIALLY ON THE BEANS!!!

PEXIVAS, PT vs. GC Injection for Knee OA, VEXAS, FAST Study

64 11 9 / 15
CAT

Harms of Short Term Steroids, VEXAS, Avacopan, FAST Study

66 11 8 / 15
Pexivasteroids are overrated

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

67 11 7 / 15
Going all the way

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, ACR Gout Guidelines

68 10 8 / 15
Rheum’s GOAT

Belimumab for Lupus Nephritis, SEMIRA, VEXAS, ACR Gout Guidelines

68 10 8 / 15
Rheum service

VEXAS, PRIME Cells, PEXIVAS, SEMIRA

68 10 8 / 15
PR3-Pointer

PEXIVAS, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

68 10 8 / 15
Rheum for improvement

VEXAS, PRIME Cells, Belimumab for Lupus Nephritis, SEMIRA

68 10 8 / 15
 NAR — NAR12

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

73 9 8 / 15
Rheum To Improve

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, PRIME Cells

73 9 8 / 15
Adam Taylor

PEXIVAS, Harms of Short Term Steroids, VEXAS, FAST Study

75 9 7 / 15
Doodle

Harms of Short Term Steroids, VEXAS, Avacopan, PRIME Cells

75 9 7 / 15
Wait, this isn’t NephMadness…

VEXAS, Harms of Short Term Steroids, Avacopan, Synovial B Cells & Therapy Response

75 9 7 / 15
Rheum Warrior

PEXIVAS, SEMIRA, VEXAS, ACR Gout Guidelines

75 9 7 / 15
Killing the wolf : Beyond steroids

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

75 9 7 / 15
U of RA

PRIME Cells, VEXAS, PEXIVAS, PT vs. GC Injection for Knee OA

80 8 7 / 15
BadgerRheum

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, UK Frost for Frozen Shoulder

80 8 7 / 15
 Blysfull thinking — patelaarat

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

80 8 7 / 15
Nayan Arora

Belimumab for Lupus Nephritis, SEMIRA, Anti-CD38 in Refractory SLE, PRIME Cells

80 8 7 / 15
Going BLYSful

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

80 8 7 / 15
T-Rex cell in Helper CT

VEXAS, PRIME Cells, Avacopan, Harms of Short Term Steroids

85 8 6 / 15
SLE For the Win

Anti-CD38 in Refractory SLE, PRIME Cells, Belimumab for Lupus Nephritis, PT vs. GC Injection for Knee OA

86 7 7 / 15
CINDERELLA SEMIRA 86 7 7 / 9
christian laettner’s buzzer beater

VEXAS, PRIME Cells, PEXIVAS, UK Frost for Frozen Shoulder

88 7 6 / 15
Wiseguy

PEXIVAS, Harms of Short Term Steroids, IgG4-RD Classification Criteria, FAST Study

88 7 6 / 15
The Rheum Dark Horse

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, ACR Gout Guidelines

88 7 6 / 15
UBA-WON

VEXAS, ACR Gout Guidelines, PEXIVAS, Harms of Short Term Steroids

88 7 6 / 15
iheartkidneys

Belimumab for Lupus Nephritis, ACR Gout Guidelines, VEXAS, Harms of Short Term Steroids

88 7 6 / 15
Stacy Bagrova

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

88 7 6 / 15
SJB

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

94 6 6 / 15
 U of RheUtahlogy — ShrewdFanfare

ACR Gout Guidelines, Belimumab for Lupus Nephritis, Anti-CD38 in Refractory SLE, PT vs. GC Injection for Knee OA

94 6 6 / 15
Blissful champion

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

94 6 6 / 15
Rheum 2 Grow

PEXIVAS, ACR Gout Guidelines, VEXAS, PT vs. GC Injection for Knee OA

97 6 5 / 15
Phat Jointz

PT vs. GC Injection for Knee OA, PEXIVAS, Anti-CD38 in Refractory SLE, FAST Study

97 6 5 / 15
Rheuminator 3: Rise of the MABs

VEXAS, PRIME Cells, PEXIVAS, Harms of Short Term Steroids

97 6 5 / 15
Rheuma-zooma-tology

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

97 6 5 / 15
Untitled

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

101 5 5 / 15
Matthew Sparks

ACR Gout Guidelines, PEXIVAS, VEXAS, Harms of Short Term Steroids

102 5 4 / 15
Rheumatology is our daddy

VEXAS, ACR Gout Guidelines, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

102 5 4 / 15
B -cause B cells are the BEST!

Synovial B Cells & Therapy Response, IgG4-RD Classification Criteria, PEXIVAS, SEMIRA

102 5 4 / 15
Rheum Over Milwaukee

PEXIVAS, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

102 5 4 / 15
LeadershipTest2

Belimumab for Lupus Nephritis, Harms of Short Term Steroids, IgG4-RD Classification Criteria, PRIME Cells

106 4 4 / 15
Cut it gout you guys

ACR Gout Guidelines, IgG4-RD Classification Criteria, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

106 4 4 / 15
WHY PLEXING IS VEXING??

PEXIVAS, PT vs. GC Injection for Knee OA,

108 3 3 / 8
Synovial B cells

Synovial B Cells & Therapy Response, Anifrolumab, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

109 1 1 / 15

IgG Four Results!

The Rheum Ribbon Panel votes for the IgG Four (round 3) are shown below (winners in orange).

Keep scrolling to find out how your bracket is doing, then tell us your reaction on Twitter and/or the Facebook group using #RheumMadness.

Click here for a downloadable PDF of the IgG Four results

Next up:

  • Championship (the Interleukin Two) results will be released Monday, 4/5 at 8pm ET.

How is your bracket doing?

Scroll down to find your bracket title, rank, score, and the score potential that you could end up with if all of the rest of your picks are correct.

Each bracket title is a link that takes you to the Challonge.com site where you will be able to see all of the predictions entered for that bracket.  Try clicking on some of the leaders and to guess who you think might win!

Note: Some of the brackets were not given a title when they were submitted.  If you can’t find your bracket (or you don’t remember what you named it), please email david.leverenz@duke.edu and we will help you find and/or name your bracket.

You can also find even more detailed bracket results directly on the Challonge website here: https://challonge.com/RheumMadness2021/predictions

  Rank Score Score Potential
Rheum BOSS

Avacopan, FAST Study, VEXAS, SEMIRA

1 24 32
No Rheum For Error

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

2 22 30
May the best man win!

Avacopan, FAST Study, VEXAS, SEMIRA

3 22 30
Sinead Maguire

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

4 21 29
Advocate FTW

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

4 21 29
Avacopan ftw

Avacopan, FAST Study, VEXAS, SEMIRA

6 21 29
Cut the nets/steoids

Avacopan, SEMIRA, VEXAS, FAST Study

7 20 28
RheumMadnessIsAwesome

Avacopan, SEMIRA, VEXAS, FAST Study

7 20 28
RheumWins

Avacopan, SEMIRA, VEXAS, FAST Study

7 20 28
Rheumothorax

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

10 20 28
Rookie C5a inhibitor edges out SAMIRA with its promise of vasculitis remission AND less steroids. A finals match-up showing that we are FINALly moving beyond high dose steroids.

Avacopan, SEMIRA, VEXAS, FAST Study

11 19 27
KWB

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

12 19 27
Resident gone (Rheum)Mad

SEMIRA, Avacopan, VEXAS, FAST Study

13 18 18
 Fabulous FebuX — magnifique2020

FAST Study, Avacopan, IgG4-RD Classification Criteria, UK Frost for Frozen Shoulder

14 18 26
 Prednisone is Poison — mightymab

Avacopan, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

14 18 26
DFM

Avacopan, PRIME Cells, VEXAS, SEMIRA

16 17 25
CCHMC Peds Rheum Fellows

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

16 17 25
Game of Madness: To Conquer to Rule

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

16 17 25
Dr. Willie

Avacopan, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

16 17 25
What’s a bracket?

Avacopan, ACR Gout Guidelines, VEXAS, SEMIRA

16 17 25
Vasculitis winner

PEXIVAS, FAST Study, VEXAS, SEMIRA

21 17 17
Untitled

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

22 17 25
 AvaPoCan! — Thanks4theComplement

Avacopan, SEMIRA, VEXAS, ACR Gout Guidelines

23 16 24
Blys FTW

Belimumab for Lupus Nephritis, FAST Study, VEXAS, SEMIRA

24 16 16
 My Winning Prediction — StephenSlade

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

25 15 23
Just Dua It

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

25 15 23
Avocopan Avengers

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

25 15 23
Avacopan Beats Knee PT at the Buzzer

Avacopan, PT vs. GC Injection for Knee OA, IgG4-RD Classification Criteria, FAST Study

25 15 23
Untitled

PEXIVAS, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

29 15 15
Vexas for win

VEXAS, FAST Study, Belimumab for Lupus Nephritis, SEMIRA

30 15 15
Rheum_L

VEXAS, PRIME Cells, Avacopan, SEMIRA

31 14 14
 LeadershipTest — DavidLeverenz

FAST Study, RP Subtypes, Avacopan, PT vs. GC Injection for Knee OA

32 14 22
Ruairí Floyd Prediction

Avacopan, Harms of Short Term Steroids, VEXAS, PRIME Cells

32 14 22
Didem

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

32 14 22
All About Avacopan

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

32 14 22
Perry Fuchs’ Bracket

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

32 14 22
 CYCBI — ChangUCanSpare

Avacopan, SEMIRA, Anti-CD38 in Refractory SLE, Synovial B Cells & Therapy Response

32 14 22
Rheum’sYourDaddy

Avacopan, Synovial B Cells & Therapy Response, VEXAS, PT vs. GC Injection for Knee OA

32 14 22
Criscione for the “W”

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, SEMIRA

39 14 14
Get VEXED by VEXAS!

VEXAS, FAST Study, PEXIVAS, PT vs. GC Injection for Knee OA

39 14 14
Belim u me

Belimumab for Lupus Nephritis, FAST Study, VEXAS, Harms of Short Term Steroids

39 14 14
Irelande Douze Pointes

Avacopan, Harms of Short Term Steroids, VEXAS, FAST Study

42 14 22
 ESR — esr_

VEXAS, SEMIRA, Avacopan, ACR Gout Guidelines

43 13 13
Guy Katz

VEXAS, PRIME Cells, Avacopan, SEMIRA

43 13 13
 psufka — paulsufka

Avacopan, UK Frost for Frozen Shoulder, IgG4-RD Classification Criteria, FAST Study

45 13 21
Avacopanhandle

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

45 13 21
Rheumania

Avacopan, Harms of Short Term Steroids, VEXAS, Synovial B Cells & Therapy Response

45 13 21
gOUTisIN

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

48 13 13
idkijustlikegout

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

48 13 13
Void the ‘Roid

SEMIRA, Avacopan, RP Subtypes, FAST Study

50 13 13
Tincan

VEXAS, PT vs. GC Injection for Knee OA, Avacopan, FAST Study

51 12 12
Roid Rules

Synovial B Cells & Therapy Response, VEXAS, Avacopan, SEMIRA

51 12 12
“Bye Bye Bye” Steroids

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, Harms of Short Term Steroids

53 12 20
XxFlare_BearxX

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

53 12 20
Nostradamus

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

55 12 20
Penelope Proactive Patient’s Prediction

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

55 12 20
Rheumba

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

55 12 20
Rheum’sYourDaddy

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

55 12 20
No Rheum for Steroids!

PEXIVAS, FAST Study, Anti-CD38 in Refractory SLE, SEMIRA

59 12 12
NETosis: what is dead may never die

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, PRIME Cells

60 11 11
PLEXING CAN BE TAXING AND NEEDLESS ESPECIALLY ON THE BEANS!!!

PEXIVAS, PT vs. GC Injection for Knee OA, VEXAS, FAST Study

60 11 11
CAT

Harms of Short Term Steroids, VEXAS, Avacopan, FAST Study

62 11 11
Rheum for Rheum Madness

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

63 11 19
 GoComplements — saikrishna133

Avacopan, Harms of Short Term Steroids, IgG4-RD Classification Criteria, Synovial B Cells & Therapy Response

63 11 19
Pexivasteroids are overrated

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

65 11 11
Avacopan for ANCA vasculitis… now have to spell it right!

Avacopan, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

66 11 19
Going all the way

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, ACR Gout Guidelines

67 10 10
Rheum’s GOAT

Belimumab for Lupus Nephritis, SEMIRA, VEXAS, ACR Gout Guidelines

67 10 10
Rheum service

VEXAS, PRIME Cells, PEXIVAS, SEMIRA

67 10 10
PR3-Pointer

PEXIVAS, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

67 10 10
Rheum for improvement

VEXAS, PRIME Cells, Belimumab for Lupus Nephritis, SEMIRA

67 10 10
Rheumie

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

72 10 18
 NAR — NAR12

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

73 9 9
Rheum To Improve

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, PRIME Cells

73 9 9
Adam Taylor

PEXIVAS, Harms of Short Term Steroids, VEXAS, FAST Study

75 9 9
Doodle

Harms of Short Term Steroids, VEXAS, Avacopan, PRIME Cells

75 9 9
Wait, this isn’t NephMadness…

VEXAS, Harms of Short Term Steroids, Avacopan, Synovial B Cells & Therapy Response

75 9 9
Rheum Warrior

PEXIVAS, SEMIRA, VEXAS, ACR Gout Guidelines

75 9 9
Killing the wolf : Beyond steroids

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

75 9 9
U of RA

PRIME Cells, VEXAS, PEXIVAS, PT vs. GC Injection for Knee OA

80 8 8
BadgerRheum

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, UK Frost for Frozen Shoulder

80 8 8
 Blysfull thinking — patelaarat

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

80 8 8
Nayan Arora

Belimumab for Lupus Nephritis, SEMIRA, Anti-CD38 in Refractory SLE, PRIME Cells

80 8 8
Going BLYSful

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

80 8 8
T-Rex cell in Helper CT

VEXAS, PRIME Cells, Avacopan, Harms of Short Term Steroids

85 8 8
SLE For the Win

Anti-CD38 in Refractory SLE, PRIME Cells, Belimumab for Lupus Nephritis, PT vs. GC Injection for Knee OA

86 7 7
CINDERELLA SEMIRA 86 7 7
christian laettner’s buzzer beater

VEXAS, PRIME Cells, PEXIVAS, UK Frost for Frozen Shoulder

88 7 7
Wiseguy

PEXIVAS, Harms of Short Term Steroids, IgG4-RD Classification Criteria, FAST Study

88 7 7
The Rheum Dark Horse

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, ACR Gout Guidelines

88 7 7
UBA-WON

VEXAS, ACR Gout Guidelines, PEXIVAS, Harms of Short Term Steroids

88 7 7
iheartkidneys

Belimumab for Lupus Nephritis, ACR Gout Guidelines, VEXAS, Harms of Short Term Steroids

88 7 7
Stacy Bagrova

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

88 7 7
SJB

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

94 6 6
 U of RheUtahlogy — ShrewdFanfare

ACR Gout Guidelines, Belimumab for Lupus Nephritis, Anti-CD38 in Refractory SLE, PT vs. GC Injection for Knee OA

94 6 6
Blissful champion

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

94 6 6
Rheum 2 Grow

PEXIVAS, ACR Gout Guidelines, VEXAS, PT vs. GC Injection for Knee OA

97 6 6
Phat Jointz

PT vs. GC Injection for Knee OA, PEXIVAS, Anti-CD38 in Refractory SLE, FAST Study

97 6 6
Rheuminator 3: Rise of the MABs

VEXAS, PRIME Cells, PEXIVAS, Harms of Short Term Steroids

97 6 6
Rheuma-zooma-tology

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

97 6 6
Untitled

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

101 5 5
Matthew Sparks

ACR Gout Guidelines, PEXIVAS, VEXAS, Harms of Short Term Steroids

102 5 5
Rheumatology is our daddy

VEXAS, ACR Gout Guidelines, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

102 5 5
B -cause B cells are the BEST!

Synovial B Cells & Therapy Response, IgG4-RD Classification Criteria, PEXIVAS, SEMIRA

102 5 5
Rheum Over Milwaukee

PEXIVAS, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

102 5 5
LeadershipTest2

Belimumab for Lupus Nephritis, Harms of Short Term Steroids, IgG4-RD Classification Criteria, PRIME Cells

106 4 4
Cut it gout you guys

ACR Gout Guidelines, IgG4-RD Classification Criteria, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

106 4 4
WHY PLEXING IS VEXING??

PEXIVAS, PT vs. GC Injection for Knee OA,

108 3 3
Synovial B cells

Synovial B Cells & Therapy Response, Anifrolumab, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

109 1 1

 

Entheseal Eight Results!

The Rheum Ribbon Panel votes for the Entheseal Eight (round 2) are shown below (winners in orange).

Keep scrolling to find out how your bracket is doing, then tell us your reaction on Twitter and/or the Facebook group using #RheumMadness.  We will record a RheumMadness podcast episode on Tuesday evening summarizing rounds 1 and 2 and your reactions to the results.

Click here for a downloadable PDF of the Entheseal Eight results

Next up:

  • Round 3 (the IgG Four) results will be released Saturday, 4/3 at 2pm ET.
  • Round 4 (the Interleukin Two) results will be released Monday, 4/5 at 8pm ET.

How is your bracket doing?

Scroll down to find your bracket title, rank, score, and the score potential that you could end up with if all of the rest of your picks are correct.

Each bracket title is a link that takes you to the Challonge.com site where you will be able to see all of the predictions entered for that bracket.  Try clicking on some of the leaders and to guess who you think might win!

Note: Some of the brackets were not given a title when they were submitted.  If you can’t find your bracket (or you don’t remember what you named it), please email david.leverenz@duke.edu and we will help you find and/or name your bracket.

You can also find even more detailed bracket results directly on the Challonge website here: https://challonge.com/RheumMadness2021/predictions

  Rank Score Score Potential
Rheum BOSS

Avacopan, FAST Study, VEXAS, SEMIRA

1 16 32
Cut the nets/steoids

Avacopan, SEMIRA, VEXAS, FAST Study

1 16 32
RheumMadnessIsAwesome

Avacopan, SEMIRA, VEXAS, FAST Study

1 16 32
RheumWins

Avacopan, SEMIRA, VEXAS, FAST Study

1 16 32
Rookie C5a inhibitor edges out SAMIRA with its promise of vasculitis remission AND less steroids. A finals match-up showing that we are FINALly moving beyond high dose steroids.

Avacopan, SEMIRA, VEXAS, FAST Study

5 15 31
No Rheum For Error

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

6 14 30
Rheum_L

VEXAS, PRIME Cells, Avacopan, SEMIRA

7 14 26
May the best man win!

Avacopan, FAST Study, VEXAS, SEMIRA

8 14 30
Resident gone (Rheum)Mad

SEMIRA, Avacopan, VEXAS, FAST Study

8 14 30
Sinead Maguire

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

10 13 29
CCHMC Peds Rheum Fellows

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

10 13 29
Game of Madness: To Conquer to Rule

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

10 13 29
Advocate FTW

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

10 13 29
 ESR — esr_

VEXAS, SEMIRA, Avacopan, ACR Gout Guidelines

10 13 29
DFM

Avacopan, PRIME Cells, VEXAS, SEMIRA

15 13 25
Guy Katz

VEXAS, PRIME Cells, Avacopan, SEMIRA

15 13 25
Dr. Willie

Avacopan, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

15 13 25
What’s a bracket?

Avacopan, ACR Gout Guidelines, VEXAS, SEMIRA

15 13 25
Vasculitis winner

PEXIVAS, FAST Study, VEXAS, SEMIRA

19 13 17
Avacopan ftw

Avacopan, FAST Study, VEXAS, SEMIRA

20 13 29
Rheumothorax

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

21 12 28
 AvaPoCan! — Thanks4theComplement

Avacopan, SEMIRA, VEXAS, ACR Gout Guidelines

21 12 28
Tincan

VEXAS, PT vs. GC Injection for Knee OA, Avacopan, FAST Study

23 12 24
Roid Rules

Synovial B Cells & Therapy Response, VEXAS, Avacopan, SEMIRA

24 12 16
Blys FTW

Belimumab for Lupus Nephritis, FAST Study, VEXAS, SEMIRA

24 12 16
NETosis: what is dead may never die

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, PRIME Cells

26 11 27
 My Winning Prediction — StephenSlade

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

27 11 23
Just Dua It

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

27 11 23
Avocopan Avengers

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

27 11 23
Avacopan Beats Knee PT at the Buzzer

Avacopan, PT vs. GC Injection for Knee OA, IgG4-RD Classification Criteria, FAST Study

27 11 23
Untitled

PEXIVAS, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

31 11 15
PLEXING CAN BE TAXING AND NEEDLESS ESPECIALLY ON THE BEANS!!!

PEXIVAS, PT vs. GC Injection for Knee OA, VEXAS, FAST Study

32 11 11
KWB

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

33 11 27
Vexas for win

VEXAS, FAST Study, Belimumab for Lupus Nephritis, SEMIRA

33 11 27
CAT

Harms of Short Term Steroids, VEXAS, Avacopan, FAST Study

35 11 15
 Fabulous FebuX — magnifique2020

FAST Study, Avacopan, IgG4-RD Classification Criteria, UK Frost for Frozen Shoulder

36 10 26
Going all the way

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, ACR Gout Guidelines

36 10 26
Get VEXED by VEXAS!

VEXAS, FAST Study, PEXIVAS, PT vs. GC Injection for Knee OA

36 10 26
 CYCBI — ChangUCanSpare

Avacopan, SEMIRA, Anti-CD38 in Refractory SLE, Synovial B Cells & Therapy Response

36 10 26
 Prednisone is Poison — mightymab

Avacopan, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

36 10 26
 LeadershipTest — DavidLeverenz

FAST Study, RP Subtypes, Avacopan, PT vs. GC Injection for Knee OA

41 10 22
Ruairí Floyd Prediction

Avacopan, Harms of Short Term Steroids, VEXAS, PRIME Cells

41 10 22
Didem

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

41 10 22
All About Avacopan

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

41 10 22
Perry Fuchs’ Bracket

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

41 10 22
Rheum service

VEXAS, PRIME Cells, PEXIVAS, SEMIRA

41 10 22
Rheum’sYourDaddy

Avacopan, Synovial B Cells & Therapy Response, VEXAS, PT vs. GC Injection for Knee OA

41 10 22
Rheum for improvement

VEXAS, PRIME Cells, Belimumab for Lupus Nephritis, SEMIRA

41 10 22
Criscione for the “W”

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, SEMIRA

49 10 14
Rheum’s GOAT

Belimumab for Lupus Nephritis, SEMIRA, VEXAS, ACR Gout Guidelines

49 10 14
Belim u me

Belimumab for Lupus Nephritis, FAST Study, VEXAS, Harms of Short Term Steroids

49 10 14
PR3-Pointer

PEXIVAS, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

49 10 14
Irelande Douze Pointes

Avacopan, Harms of Short Term Steroids, VEXAS, FAST Study

53 10 22
Rheum To Improve

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, PRIME Cells

54 9 13
 NAR — NAR12

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

55 9 9
 psufka — paulsufka

Avacopan, UK Frost for Frozen Shoulder, IgG4-RD Classification Criteria, FAST Study

56 9 21
Avacopanhandle

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

56 9 21
Wait, this isn’t NephMadness…

VEXAS, Harms of Short Term Steroids, Avacopan, Synovial B Cells & Therapy Response

56 9 21
Rheumania

Avacopan, Harms of Short Term Steroids, VEXAS, Synovial B Cells & Therapy Response

56 9 21
Doodle

Harms of Short Term Steroids, VEXAS, Avacopan, PRIME Cells

60 9 13
Rheum Warrior

PEXIVAS, SEMIRA, VEXAS, ACR Gout Guidelines

60 9 13
gOUTisIN

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

60 9 13
idkijustlikegout

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

60 9 13
Adam Taylor

PEXIVAS, Harms of Short Term Steroids, VEXAS, FAST Study

64 9 9
Killing the wolf : Beyond steroids

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

64 9 9
Void the ‘Roid

SEMIRA, Avacopan, RP Subtypes, FAST Study

66 9 25
Untitled

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

66 9 25
“Bye Bye Bye” Steroids

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, Harms of Short Term Steroids

68 8 20
XxFlare_BearxX

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

68 8 20
U of RA

PRIME Cells, VEXAS, PEXIVAS, PT vs. GC Injection for Knee OA

70 8 12
Nayan Arora

Belimumab for Lupus Nephritis, SEMIRA, Anti-CD38 in Refractory SLE, PRIME Cells

70 8 12
BadgerRheum

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, UK Frost for Frozen Shoulder

72 8 8
 Blysfull thinking — patelaarat

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

72 8 8
Going BLYSful

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

72 8 8
Nostradamus

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

75 8 20
Penelope Proactive Patient’s Prediction

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

75 8 20
Rheumba

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

75 8 20
T-Rex cell in Helper CT

VEXAS, PRIME Cells, Avacopan, Harms of Short Term Steroids

75 8 20
Rheum’sYourDaddy

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

75 8 20
No Rheum for Steroids!

PEXIVAS, FAST Study, Anti-CD38 in Refractory SLE, SEMIRA

80 8 12
SLE For the Win

Anti-CD38 in Refractory SLE, PRIME Cells, Belimumab for Lupus Nephritis, PT vs. GC Injection for Knee OA

81 7 7
CINDERELLA SEMIRA 81 7 7
Rheum for Rheum Madness

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

83 7 19
christian laettner’s buzzer beater

VEXAS, PRIME Cells, PEXIVAS, UK Frost for Frozen Shoulder

83 7 19
 GoComplements — saikrishna133

Avacopan, Harms of Short Term Steroids, IgG4-RD Classification Criteria, Synovial B Cells & Therapy Response

83 7 19
UBA-WON

VEXAS, ACR Gout Guidelines, PEXIVAS, Harms of Short Term Steroids

83 7 19
The Rheum Dark Horse

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, ACR Gout Guidelines

87 7 11
Pexivasteroids are overrated

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

87 7 11
Wiseguy

PEXIVAS, Harms of Short Term Steroids, IgG4-RD Classification Criteria, FAST Study

89 7 7
Untitled

Belimumab for Lupus Nephritis, ACR Gout Guidelines, VEXAS, Harms of Short Term Steroids

89 7 7
Stacy Bagrova

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

89 7 7
Avacopan for ANCA vasculitis… now have to spell it right!

Avacopan, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

92 7 19
SJB

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

93 6 6
 U of RheUtahlogy — ShrewdFanfare

ACR Gout Guidelines, Belimumab for Lupus Nephritis, Anti-CD38 in Refractory SLE, PT vs. GC Injection for Knee OA

93 6 6
Blissful champion

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

93 6 6
Rheuminator 3: Rise of the MABs

VEXAS, PRIME Cells, PEXIVAS, Harms of Short Term Steroids

96 6 18
Rheumie

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

96 6 18
Rheum 2 Grow

PEXIVAS, ACR Gout Guidelines, VEXAS, PT vs. GC Injection for Knee OA

98 6 6
Phat Jointz

PT vs. GC Injection for Knee OA, PEXIVAS, Anti-CD38 in Refractory SLE, FAST Study

98 6 6
Rheuma-zooma-tology

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

98 6 6
Untitled

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

101 5 5
Rheumatology is our daddy

VEXAS, ACR Gout Guidelines, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

102 5 17
Matthew Sparks

ACR Gout Guidelines, PEXIVAS, VEXAS, Harms of Short Term Steroids

103 5 5
B -cause B cells are the BEST!

Synovial B Cells & Therapy Response, IgG4-RD Classification Criteria, PEXIVAS, SEMIRA

103 5 5
Rheum Over Milwaukee

PEXIVAS, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

103 5 5
LeadershipTest2

Belimumab for Lupus Nephritis, Harms of Short Term Steroids, IgG4-RD Classification Criteria, PRIME Cells

106 4 4
Cut it gout you guys

ACR Gout Guidelines, IgG4-RD Classification Criteria, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

106 4 4
WHY PLEXING IS VEXING??

PEXIVAS, PT vs. GC Injection for Knee OA,

108 3 3
Synovial B cells

Synovial B Cells & Therapy Response, Anifrolumab, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

109 1 1

Seronegative Sixteen Results!

The Blue Ribbon Panel votes for the Seronegative Sixteen (round 1) are shown below (winner in orange).  This round was so close!  Five of the match-ups were decided by a 4-3 vote.

Round 2 results will be released Monday, 4/29 at 8pm ET.

Keep scrolling to find out how your bracket is doing, then tell us your reaction on Twitter and/or the Facebook group using #RheumMadness.  We will record a RheumMadness podcast episode on Tuesday evening summarizing rounds 1 and 2 and your reactions to the results.  The fun and the learning are just beginning!

Click here for a downloadable PDF of the Seronegative Sixteen Results

Results can also be found here: https://challonge.com/RheumMadness2021

How is your bracket doing?

Scroll down to find your bracket title, rank, score, and the score potential that you could end up with if all of the rest of your picks are correct.

Each bracket title is a link that takes you to the Challonge.com site where you will be able to see all of the predictions entered for that bracket.  Try clicking on some of the leaders and to guess who you think might win!

***Note*** – some of the brackets were not given a title when they were submitted.  If you can’t find your bracket (or you don’t remember what you named it), please email david.leverenz@duke.edu and we will help you find and/or name your bracket.

You can also find bracket results directly on the Challonge website here: https://challonge.com/RheumMadness2021/predictions

Bracket Title

(Final 4 Prediction with Winner Underlined)

Rank Score Score Potential
Rheum BOSS

Avacopan, FAST Study, VEXAS, SEMIRA

1 8 32
Rheum_L

VEXAS, PRIME Cells, Avacopan, SEMIRA

1 8 32
Cut the nets/steoids

Avacopan, SEMIRA, VEXAS, FAST Study

1 8 32
RheumMadnessIsAwesome

Avacopan, SEMIRA, VEXAS, FAST Study

1 8 32
RheumWins

Avacopan, SEMIRA, VEXAS, FAST Study

1 8 32
No Rheum For Error

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

1 8 32
DFM

Avacopan, PRIME Cells, VEXAS, SEMIRA

7 7 31
My Winning Prediction StephenSlade

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

7 7 31
Just Dua It

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

7 7 31
NETosis: what is dead may never die

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, PRIME Cells

7 7 31
Guy Katz

VEXAS, PRIME Cells, Avacopan, SEMIRA

7 7 31
Rookie C5a inhibitor edges out SAMIRA with its promise of vasculitis remission AND less steroids. A finals match-up showing that we are FINALly moving beyond high dose steroids.

Avacopan, SEMIRA, VEXAS, FAST Study

7 7 31
Avocopan Avengers

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

7 7 31
Avacopan Beats Knee PT at the Buzzer

Avacopan, PT vs. GC Injection for Knee OA, IgG4-RD Classification Criteria, FAST Study

7 7 31
Sinead Maguire

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

15 7 29
CCHMC Peds Rheum Fellows

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

15 7 29
Game of Madness: To Conquer to Rule

Avacopan, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

15 7 29
Advocate FTW

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

15 7 29
ESR esr_

VEXAS, SEMIRA, Avacopan, ACR Gout Guidelines

15 7 29
NAR NAR12

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

20 7 25
Dr. Willie

Avacopan, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

20 7 25
What’s a bracket?

Avacopan, ACR Gout Guidelines, VEXAS, SEMIRA

20 7 25
Untitled

PEXIVAS, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

23 7 17
SLE For the Win

Anti-CD38 in Refractory SLE, PRIME Cells, Belimumab for Lupus Nephritis, PT vs. GC Injection for Knee OA

23 7 17
Vasculitis winner

PEXIVAS, FAST Study, VEXAS, SEMIRA

23 7 17
Rheum To Improve

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, PRIME Cells

23 7 17
PLEXING CAN BE TAXING AND NEEDLESS ESPECIALLY ON THE BEANS!!!

PEXIVAS, PT vs. GC Injection for Knee OA, VEXAS, FAST Study

23 7 17
CINDERELLA SEMIRA 28 7 7
Tincan

VEXAS, PT vs. GC Injection for Knee OA, Avacopan, FAST Study

29 6 30
Rheumothorax

Avacopan, FAST Study, VEXAS, PT vs. GC Injection for Knee OA

29 6 30
May the best man win!

Avacopan, FAST Study, VEXAS, SEMIRA

29 6 30
Blys FTW

Belimumab for Lupus Nephritis, FAST Study, VEXAS, SEMIRA

29 6 30
Prednisone is Poison mightymab

Avacopan, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

29 6 30
Resident gone (Rheum)Mad

SEMIRA, Avacopan, VEXAS, FAST Study

29 6 30
Rheum for improvement

VEXAS, PRIME Cells, Belimumab for Lupus Nephritis, SEMIRA

29 6 30
SJB

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

36 6 28
U of RA

PRIME Cells, VEXAS, PEXIVAS, PT vs. GC Injection for Knee OA

36 6 28
Fabulous FebuX magnifique2020

FAST Study, Avacopan, IgG4-RD Classification Criteria, UK Frost for Frozen Shoulder

36 6 28
Didem

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

36 6 28
Going all the way

VEXAS, SEMIRA, Belimumab for Lupus Nephritis, ACR Gout Guidelines

36 6 28
Get VEXED by VEXAS!

VEXAS, FAST Study, PEXIVAS, PT vs. GC Injection for Knee OA

36 6 28
All About Avacopan

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

36 6 28
Blissful champion

Belimumab for Lupus Nephritis, PRIME Cells, IgG4-RD Classification Criteria, Harms of Short Term Steroids

36 6 28
Rheum’s GOAT

Belimumab for Lupus Nephritis, SEMIRA, VEXAS, ACR Gout Guidelines

36 6 28
Nayan Arora

Belimumab for Lupus Nephritis, SEMIRA, Anti-CD38 in Refractory SLE, PRIME Cells

36 6 28
Belim u me

Belimumab for Lupus Nephritis, FAST Study, VEXAS, Harms of Short Term Steroids

36 6 28
Rheum service

VEXAS, PRIME Cells, PEXIVAS, SEMIRA

36 6 28
AvaPoCan! Thanks4theComplement

Avacopan, SEMIRA, VEXAS, ACR Gout Guidelines

36 6 28
CYCBI ChangUCanSpare

Avacopan, SEMIRA, Anti-CD38 in Refractory SLE, Synovial B Cells & Therapy Response

49 6 26
LeadershipTest DavidLeverenz

FAST Study, RP Subtypes, Avacopan, PT vs. GC Injection for Knee OA

50 6 24
Ruairí Floyd Prediction

Avacopan, Harms of Short Term Steroids, VEXAS, PRIME Cells

50 6 24
Blysfull thinking patelaarat

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

50 6 24
XxFlare_BearxX

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

50 6 24
Going BLYSful

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

50 6 24
Rheum’sYourDaddy

Avacopan, Synovial B Cells & Therapy Response, VEXAS, PT vs. GC Injection for Knee OA

50 6 24
“Bye Bye Bye” Steroids

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, Harms of Short Term Steroids

56 6 22
BadgerRheum

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, UK Frost for Frozen Shoulder

56 6 22
Perry Fuchs’ Bracket

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

56 6 22
Roid Rules

Synovial B Cells & Therapy Response, VEXAS, Avacopan, SEMIRA

59 6 16
Criscione for the “W”

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, SEMIRA

59 6 16
U of RheUtahlogy ShrewdFanfare

ACR Gout Guidelines, Belimumab for Lupus Nephritis, Anti-CD38 in Refractory SLE, PT vs. GC Injection for Knee OA

61 6 14
PR3-Pointer

PEXIVAS, SEMIRA, VEXAS, Synovial B Cells & Therapy Response

61 6 14
Avacopan ftw

Avacopan, FAST Study, VEXAS, SEMIRA

63 5 29
Vexas for win

VEXAS, FAST Study, Belimumab for Lupus Nephritis, SEMIRA

63 5 29
KWB

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

65 5 27
Avacopanhandle

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

65 5 27
christian laettner’s buzzer beater

VEXAS, PRIME Cells, PEXIVAS, UK Frost for Frozen Shoulder

67 5 25
psufka paulsufka

Avacopan, UK Frost for Frozen Shoulder, IgG4-RD Classification Criteria, FAST Study

68 5 23
Rheum for Rheum Madness

Avacopan, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

68 5 23
Killing the wolf : Beyond steroids

Belimumab for Lupus Nephritis, Synovial B Cells & Therapy Response, VEXAS, SEMIRA

68 5 23
GoComplements saikrishna133

Avacopan, Harms of Short Term Steroids, IgG4-RD Classification Criteria, Synovial B Cells & Therapy Response

71 5 21
Wait, this isn’t NephMadness…

VEXAS, Harms of Short Term Steroids, Avacopan, Synovial B Cells & Therapy Response

71 5 21
Rheumania

Avacopan, Harms of Short Term Steroids, VEXAS, Synovial B Cells & Therapy Response

71 5 21
iheartkidneys

Belimumab for Lupus Nephritis, ACR Gout Guidelines, VEXAS, Harms of Short Term Steroids

71 5 21
UBA-WON

VEXAS, ACR Gout Guidelines, PEXIVAS, Harms of Short Term Steroids

75 5 19
CAT

Harms of Short Term Steroids, VEXAS, Avacopan, FAST Study

76 5 15
Doodle

Harms of Short Term Steroids, VEXAS, Avacopan, PRIME Cells

76 5 15
Pexivasteroids are overrated

PEXIVAS, FAST Study, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

76 5 15
gOUTisIN

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

76 5 15
idkijustlikegout

ACR Gout Guidelines, Avacopan, VEXAS, PT vs. GC Injection for Knee OA

76 5 15
The Rheum Dark Horse

PEXIVAS, SEMIRA, IgG4-RD Classification Criteria, ACR Gout Guidelines

81 5 13
Rheum Warrior

PEXIVAS, SEMIRA, VEXAS, ACR Gout Guidelines

81 5 13
Adam Taylor

PEXIVAS, Harms of Short Term Steroids, VEXAS, FAST Study

83 5 9
Untitled

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, PT vs. GC Injection for Knee OA

83 5 9
Wiseguy

PEXIVAS, Harms of Short Term Steroids, IgG4-RD Classification Criteria, FAST Study

83 5 9
Stacy Bagrova

PEXIVAS, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

83 5 9
Rheum’sYourDaddy

Avacopan, PRIME Cells, VEXAS, PT vs. GC Injection for Knee OA

87 4 28
Nostradamus

Avacopan, PRIME Cells, VEXAS, Harms of Short Term Steroids

88 4 26
Penelope Proactive Patient’s Prediction

Avacopan, PT vs. GC Injection for Knee OA, VEXAS, ACR Gout Guidelines

88 4 26
T-Rex cell in Helper CT

VEXAS, PRIME Cells, Avacopan, Harms of Short Term Steroids

88 4 26
Rheuminator 3: Rise of the MABs

VEXAS, PRIME Cells, PEXIVAS, Harms of Short Term Steroids

91 4 24
Irelande Douze Pointes

Avacopan, Harms of Short Term Steroids, VEXAS, FAST Study

92 4 22
LeadershipTest2

Belimumab for Lupus Nephritis, Harms of Short Term Steroids, IgG4-RD Classification Criteria, PRIME Cells

92 4 22
Rheuma-zooma-tology

Belimumab for Lupus Nephritis, ACR Gout Guidelines, IgG4-RD Classification Criteria, SEMIRA

92 4 22
Phat Jointz

PT vs. GC Injection for Knee OA, PEXIVAS, Anti-CD38 in Refractory SLE, FAST Study

95 4 20
Rheumba

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, SEMIRA

95 4 20
Rheumie

Avacopan, ACR Gout Guidelines, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

97 4 18
No Rheum for Steroids!

PEXIVAS, FAST Study, Anti-CD38 in Refractory SLE, SEMIRA

98 4 12
Cut it gout you guys

ACR Gout Guidelines, IgG4-RD Classification Criteria, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

98 4 12
Rheum 2 Grow

PEXIVAS, ACR Gout Guidelines, VEXAS, PT vs. GC Injection for Knee OA

100 4 8
Void the ‘Roid

SEMIRA, Avacopan, RP Subtypes, FAST Study

101 3 25
Untitled

Avacopan, FAST Study, VEXAS, Harms of Short Term Steroids

101 3 25
Rheumatology is our daddy

VEXAS, ACR Gout Guidelines, Belimumab for Lupus Nephritis, Harms of Short Term Steroids

103 3 19
Avacopan for ANCA vasculitis… now have to spell it right! (not “avacpoan” like on the list here https://sites.duke.edu/rheummadness/bracket-and-scouting-reports/ :))

Avacopan, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

103 3 19
B -cause B cells are the BEST!

Synovial B Cells & Therapy Response, IgG4-RD Classification Criteria, PEXIVAS, SEMIRA

105 3 11
Matthew Sparks

ACR Gout Guidelines, PEXIVAS, VEXAS, Harms of Short Term Steroids

106 3 5
WHY PLEXING IS VEXING??

PEXIVAS, PT vs. GC Injection for Knee OA,

106 3 5
Rheum Over Milwaukee

PEXIVAS, Synovial B Cells & Therapy Response, VEXAS, Harms of Short Term Steroids

106 3 5
Synovial B cells

Synovial B Cells & Therapy Response, Anifrolumab, Anti-CD38 in Refractory SLE, Harms of Short Term Steroids

109 1 1

PEXIVAS Scouting Report

Written by: Medical College of Wisconsin Rheumatology Fellows 

Based on: Walsh M, et al; PEXIVAS Investigators. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-631.

Topic Overview

Vasculitides are a group of diverse diseases that cause inflammation in the vasculature, with protean manifestations of potentially serious, life-threatening complications. Often categorized by size of the affected vasculature,  small vessel vasculitides can be further characterized by those associated with positive ANCA serologies, such as GPA and MPA—two very important diseases in the world of rheumatology that have unique clinical, laboratory, and histopathologic findings. Early recognition is key to preventing morbidity and mortality, and induction therapy consists of high dose steroids and immunosuppressive therapy.  However, sometimes the sequela is so dire that this is not enough, especially with respect to pulmonary hemorrhage and renal failure. In the face of complicated and high-risk clinical situations, we, as clinicians do everything to preserve a patient’s life and limit morbidity. Yet, by doing this, can we potentially be causing more harm, and is the approach “less is more” actually better?

For the first time, the PEXIVAS landmark study addressed this very question, as studies before had never assessed if plasma exchange can improve survival and reduce severe complications.  Through a large (>700 patients involved!), multi-center, randomized, two by two trial conducted over 16 countries, the study set out to answer two main questions in cohorts of patients with severe ANCA-associated vasculitis:

  1. Does plasma exchange reduce all cause death and progression to end stage renal disease (ESRD)?
  2. Are reduced dose steroids non-inferior to standard dose steroids?

The patients were randomized 1:1:1:1 to receive plasma exchange with standard dose steroids, plasma exchange with reduced dose steroids, no plasma exchange with standard dose steroids or no plasma exchange with reduced dose steroids.  All patients received induction treatment with IV cyclophosphamide, PO cyclophosphamide or IV rituximab, followed by maintenance treatment with azathioprine.  The results did not demonstrate that plasma exchange reduced the incidence of death from any cause or end stage renal disease in severe ANCA associated vasculitis.  Additionally, reduced dose steroids were found to be non-inferior to standard dose steroids.        

Implications for patients, providers, and researchers

Current implications: We, as rheumatologists, are always seeking management options that are both effective and safe, and yet sometimes, the crux of the matter is that a lot of our therapeutic options have significant side effects and potential toxicities.  We think that this trial is important as it addresses main safety sectors including death and adverse events.

The results of the study demonstrated that there was no reduced incidence of death or ESRD in patients receiving plasma exchange compared to those who did not.

Furthermore, low-dose steroids yielded non-inferior results to standard doses, and most importantly, they demonstrated overall reduced risk of serious infections. We can rapidly and cumulatively (almost by 60%!) taper steroids in our patients without losing efficacy while also reducing the risk of infections.  A common theme at the ACR conference this year was reduction of steroids, and this study further corroborated this idea that we can actively act upon to decrease infectious burden.  The very cornerstone of rheumatologic interventions is steroids, and so we think this result is indeed a game changer!

Future implications: One could argue that a limitation of the study was in the patient cohort itself, as while the study was aimed to assess the sickest in vasculitis, in truth, the patient panel was not entirely representative of the most severe forms of diffuse alveolar hemorrhage or acute renal failure.  More severe ANCA vasculitis patients were underrepresented in this trial; thus, future studies can further assess and incorporate the more ideal patient group to expound on the results.  Additionally, azathioprine was used as maintenance treatment in this study, instead of rituximab. We know from the MAINRITSAN trial that using rituximab for maintenance treatment in ANCA vasculitis prevented relapses more so than with azathioprine.  Therefore, it is possible that the results of PEXIVAS may have been different if rituximab was used for maintenance therapy.

Will it win first round?

The PEXIVAS trial was strongly designed via the two-by-two factorial design, which enabled four different groups to be analyzed. The study was also large, conducted over a long duration, and spanned across multiple countries which makes the results more universal and applicable.

While the ADVOCATE study is indeed interesting and important as a new drug to help sustain remission in vasculitis, we just do not think that the trial is as impressive as PEXIVAS. We now know that plasmapheresis does not alter morbidity and mortality, while also gaining insight that we can use a lower cumulative dose of steroids with equal efficacy and mitigation of serious infections.  Though the ADVOCATE trial shows promise for avacopan in the remission in ANCA vasculitis, this may not be readily available for use.          

Will PEXIVAS win at all?

While we do find overall strengths in this trial, we still would like to comment on some of its weaknesses. For one, it was an open-label study, and the choice of induction therapy was made prior to randomization. In theory, this could have created biases in treatment favoring cyclophosphamide over rituximab for induction if plasma exchange was given or not. The largest issue with this study is as iterated above, was that patients with severe vasculitis were hardly represented ( <10%), and thus, this study cannot be easily applied to patients with life threatening clinical manifestations.  While there are weaknesses, overall, we feel that its strengths outweigh them.

The overall winner in the competition is challenging as this assertion is sort of comparing apples to oranges as all the clinical investigations in this competition are so monumental.  However, we do feel that on the strength of our arguments, the PEXIVAS team can match and perhaps even surpass any scouting report in this competition. We anticipate a stiff competition from more fashionable diseases in rheumatology such as the investigations looking at gout, lupus nephritis and the harmful effects of short-term steroids. In the end, the PEXIVAS team will always contend that the prevention of harm to the patient is worth more than any new discoveries other trials may or may not show. Through the very nature of steroids being the cornerstone of rheumatologic interventions, we do believe this study has huge implications, both in the realm of vasculitis and likely through extension to other systemic inflammatory conditions. If we can control disease through less steroid exposure, and mitigate cumulative risk and toxicity, this can have an extensive ripple effect in potentially reducing infections, osteoporosis, avascular necrosis, and more steroid sequela as we begin to study it across other rheumatologic conditions. Let the best team win!

References:

  1. Walsh M, et al; PEXIVAS Investigators. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-631.
  2. Jayne DRW, et al; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021 Feb 18;384(7):599-609.
  3. Pagnoux C, Guillevin L; French Vasculitis Study Group; MAINRITSAN investigators. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. N Engl J Med. 2015 Jan 22;372(4):386-7.

Read More!

Click here to return to the bracket and list of scouting reports.

2021 Blue Ribbon Panel

The 2021 RheumMadness Blue Ribbon Panel is truly a special group.  Thanks to these wonderful leaders and educators for their participation!  As a reminder, the Blue Ribbon Panel will vote to choose the actual winners of each match-up in the RheumMadness tournament.  For more on how this will work, see What is RheumMadness?

Click here for a downloadable (and larger) PDF of the Blue Ribbon Panel

Meet the Panel

Tayseer Haroun, MD is a rheumatologist at the Northern Virginia Center for Arthritis.  Special interests include general rheumatology, inflammatory myopathy, and vasculitis.

Beth Laurie Jonas, MD, FACR is the Reeves Foundation Distinguished Professor of Medicine and Chief of the Division of Rheumatology, Allergy and Immunology at the University of North Carolina.

Eli Miloslavsky, MD is an Assistant Professor of Medicine at Harvard Medical School, and Co-Director of the Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital.

Michael Putman, MD, MSCI is an Assistant Professor of Medicine at the Medical College of Wisconsin.  He is also the creator of the Evidence Based Rheumatology Podcast (EBRheum) and can be found on Twitter at @EBRheum.

Jeffrey Sparks, MD, MMSc is an Associate Physician, Brigham and Women’s Hospital and Assistant Professor of Medicine, Harvard Medical School. He can be found on Twitter at @jeffsparks.

Teresa Tarrant, MD is an Associate Professor of Medicine at Duke University School of Medicine. She is also trained in allergy and immunology and can be found on Twitter at @TKTarrant.

Kristen Young, DO is a second year rheumatology fellow at the University of Texas Southwestern Medical Center. She can be found on Twitter at @kristenyoung.